Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Child-Pugh B HCC Patients After First-Line ICI Failure
NCT07514455Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC). Primary endpoint: Progression Free Survival up to 36 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07514455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514455.